Nov 01, 2022 8:30am EDT Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
Sep 15, 2022 8:30am EDT Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
Sep 07, 2022 8:30am EDT Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
Aug 16, 2022 8:30am EDT Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board
Aug 12, 2022 9:30am EDT Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 05, 2022 3:00pm EDT Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
Aug 04, 2022 9:30am EDT Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
Aug 03, 2022 4:00pm EDT Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
Jul 12, 2022 8:30am EDT Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022
May 12, 2022 4:20pm EDT Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
